Lalitha Vezrqami · Chief Strategy Officer · India
I can help a board examine the assumptions that make a strategic choice look more attractive than it is. My experience includes a growth average I corrected, a channel map whose brands concealed common ownership and an agreement whose reach came with restricted alternatives. Those are different questions, but each asks what the recommendation leaves outside its headline. My foundation appointment gives me experience of collective responsibility in an adult-learning organisation. It does not make that experience equivalent to serving on an insurer board or establish eligibility for a regulated appointment. I would bring the habit of asking which conditions support the proposal and which choices disappear once it is accepted. Management should still design the strategy and professionals should assess its financial, legal and insurance implications. The board’s contribution is to test the commitment as a whole, including its uncertainty and consequences, without becoming a second strategy office.
| Capacity | Committees |
|---|---|
| Ready to join | Strategy and commercial-dependence discussions · Distribution and investment-assumption oversight |
I would consider one additional non-executive appointment where an experienced chair wants to examine growth assumptions and strategic dependence. Company-specific eligibility and preparation must precede acceptance, particularly for a regulated or independent role. My foundation service is relevant experience to discuss, not a credential that settles those questions. I would initially contribute to strategy or commercial-risk discussions under established leadership and make no offer to chair a statutory committee. The board should explain why this perspective is needed and how it complements existing finance, insurance and legal expertise. Management must retain responsibility for the option analysis and negotiation. I would avoid a seat whose main purpose is access to distribution relationships. The contribution I seek is to help colleagues understand the choice they are making, the choices they are closing and the evidence that should cause them to reconsider.
Served as a director
Adult-learning foundation board; unpaid non-executive appointment
October 2023–present
One current statutory directorship with a six-day annual allocation. No insurance-board appointment or statutory committee chair role is claimed.
Presented to the Board or a committee
Invited strategy and distribution-choice discussions
April 2020–present
Presents management recommendations and unresolved assumptions through the CEO; not an insurer director.
The 2017 growth illustration combined a ₹100 crore segment at 20 percent with a ₹900 crore segment at 5 percent. A simple average overstated the combined rate; the weighted arithmetic yielded 6.5 percent. I would ask directors whether a corrected assumption has changed the recommendation built on it, rather than only its presentation. The growth inputs remained uncertain even after the calculation was repaired. Deferring the original programme was a management and approval-process response, not evidence of a saving equal to the unspent request. The board should be able to see the link from assumptions to resources and the conditions for reconsidering the proposal. My own error is useful in that discussion because it demonstrates that a senior sponsor can be the source of the assumption that needs challenge.
The proposed 600 outlet arrangement included two years of exclusivity, while a smaller 120 outlet route was nonexclusive and carried different costs. I would ask how directors are shown the alternatives the wider arrangement would restrict, including existing partner relationships. The smaller route did not deliver the same scope more cheaply, and authorisation did not prove its eventual profitability. Those distinctions should remain in the decision record. Legal and commercial professionals need to interpret and negotiate the actual terms; a director’s strategy experience does not replace their assessment. My contribution would be to question whether the organisation understands what it is trading away and what evidence would justify a larger commitment later, rather than promote flexibility as a benefit without accounting for the reach forgone.
I would begin with the company’s recent major choices and the reasons alternatives were rejected. Through an induction agreed with the chair, I would examine one investment case and one distribution relationship, meeting management through the established process. I would ask how scenario assumptions, ownership connections and contractual restrictions enter the recommendation, and how later evidence can reopen a decision. My existing foundation allocation of six days must remain visible beside the proposed twenty-four days for an additional role. The actual calendar, including preparation and exceptional demands, needs agreement before acceptance. I would seek feedback on whether my questions improve the board’s understanding or encourage unnecessary re-analysis of settled operational matters. A useful first-year contribution could clarify the circumstances under which a strategic commitment should return for review. It should address the company’s own priority rather than impose a favourite planning framework from my executive career.
My insurer employment provides access to distribution plans, investment arguments and partner negotiations. The promoter group, financial investor and related channel owners may have interests relevant to a potential appointment even though I hold no beneficial shares. My foundation has no commercial relationship with the insurer in this fictional account, but its funding and connections would still need examination against the receiving company. I would disclose both roles and relevant relationships before receiving protected board material. Employer consent, confidentiality and the combined calendar need practical resolution. A director must not become a route to the insurer’s partners or use the foundation appointment to advance a commercial negotiation. Recusal can manage a particular matter, but repeated exclusion from core strategy decisions might remove the value of the proposed seat. I would decline an arrangement that expects confidential market plans, preferential access or endorsement of an investment without the company’s own professional assessment and collective approval.
My executive employment, foundation appointment and insurer partner relationships require company-specific review. No shareholding does not establish independent status or eligibility for a particular committee.
IICA Independent Directors’ Databank: Not yet registered
One foundation directorship is current. Preparation and any applicable registration for an independent company-board role remain incomplete; no proficiency pass or exemption is asserted.